Evidence that the immunopathogenic mechanism of lithium-induced psoriasis differs from that of regular psoriasis.
Knijff
Esther M
EM
Kupka
Ralph W
RW
Ruwhof
Cindy
C
Breunis
M Nadine
MN
Prens
Errol P
EP
Nolen
Willem A
WA
Drexhage
Hemmo A
HA
D014150:Antipsychotic Agents / Q000009:adverse effects*; D001714:Bipolar Disorder / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007375:Interleukin-1 / Q000378:metabolism*; D015850:Interleukin-6 / Q000378:metabolism*; D018021:Lithium Chloride / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000139:chemically induced* / Q000276:immunology*; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism*
D014150:Antipsychotic Agents; D007375:Interleukin-1; D015850:Interleukin-6; D014409:Tumor Necrosis Factor-alpha; D018021:Lithium Chloride